SARTF (Sartorius AG) Other Current Liabilities: $795 Mil (As of Mar. 2026)


SARTF Sartorius AG SARTF
85 GF Score
Price $212.80
GF Value $234.29
Valuation Fairly Valued
! 9 Warning Signs
View Full Analysis

What is Sartorius AG Other Current Liabilities?

Sartorius AG SARTF 85 Other Current Liabilities is $795 Mil as of Mar. 2026. GuruFocus rates SARTF with a GF Score™ of 85/100 and a GF Value™ of $234.29 (Fairly Valued). The stock has 9 warning signs investors should review.

Sartorius AG's other current liabilities for the quarter that ended in Mar. 2026 was $795 Mil.

Sartorius AG's quarterly other current liabilities increased from Sep. 2025 ($604 Mil) to Dec. 2025 ($644 Mil) and increased from Dec. 2025 ($644 Mil) to Mar. 2026 ($795 Mil).

Sartorius AG's annual other current liabilities increased from Dec. 2023 ($528 Mil) to Dec. 2024 ($536 Mil) and increased from Dec. 2024 ($536 Mil) to Dec. 2025 ($644 Mil).

Sartorius AG Other Current Liabilities Related Terms

Sartorius AG Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Sartorius AG's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sartorius AG Other Current Liabilities Chart

Sartorius AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 521.47 447.25 527.70 535.92 644.50

Sartorius AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 638.70 579.01 603.99 644.50 795.03
SARTF
85GF Score
Sartorius AG SARTF
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sartorius AG Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of $795 Mil mean?
Sartorius AG (SARTF) has a Other Current Liabilities of $795 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Sartorius AG.
Is Sartorius AG's Other Current Liabilities too high?
Sartorius AG's current Other Current Liabilities is $795 Mil. Overall, Sartorius AG has a GF Score™ of 85/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sartorius AG's Other Current Liabilities compare to ISRG and BDX?
Sartorius AG's Other Current Liabilities of $795 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Medical Devices & Instruments company?
A good Other Current Liabilities depends on the Medical Devices & Instruments industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Sartorius AG. Sartorius AG's current Other Current Liabilities is $795 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius AG stock overvalued right now?
Based on GuruFocus' analysis, Sartorius AG (SARTF) is currently considered Fairly Valued. The stock's GF Value™ is $234.29, compared to a current price of $212.80 — trading 9.2% below its estimated fair value. The current Other Current Liabilities is $795 Mil. Sartorius AG's overall GF Score™ is 85/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Sartorius AG (SARTF), the current Other Current Liabilities is $795 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sartorius AG (SARTF) Overvalued in 2026?

Based on GuruFocus' analysis, Sartorius AG stock appears to be undervalued. The current stock price of $212.80 is trading 9.2% below its estimated GF Value™ of $234.29. GuruFocus considers Sartorius AG to be Fairly Valued.

Key valuation signals for SARTF:

  • Other Current Liabilities: $795 Mil
  • GF Value™: $234.29 vs. price of $212.80 (9.2% below fair value)
  • GF Score™: 85/100 with 9 warning signs

No single metric tells the full story. See the SARTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sartorius AG Business Description

Address Otto-Brenner-Strasse 20, Gottingen, NI, DEU, 37079
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs and focuses on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
85GF Score

Get the complete analysis for SARTF

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$212.80
Price
$234.29
GF Value